Biotechnology
Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment
* Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. * The candidate is intended to be used for the treatment of SARS-CoV-2 and its variants, along with other coronaviruses. * ...
2022-05-25 05:00
2217
ICP DAS - BMP will attend Medical Taiwan Expo 2022 in Taipei
TAIPEI, May 25, 2022 /PRNewswire/ -- ICP DAS - BMP (Biomedical Polymers), a Taiwanese medical TPU (thermoplastic polyurethane) supplier, will exhibit at Medical Taiwan 2022, an international medical, health, and care expo. The Medical Taiwan Expo 2022 will take place at the Taipei Nangang Exhibit...
2022-05-25 01:25
3456
Eurofins Discovery Announces Formation of its New Scientific Advisory Board
SAN DIEGO, May 24, 2022 /PRNewswire/ -- Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, today announced the formation of its new Scientific Advisory Board (SAB). Company officials gathered renowned lead...
2022-05-24 23:00
2397
Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment
* Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. * The candidate is intended to be used for the treatment of SARS-CoV-2 and its variants, along with other coronaviruses. Insi...
2022-05-24 21:00
2411
Travecta Therapeutics Announces In-Person Presentation at 2022 BIO International Convention
SINGAPORE and PRINCETON, N.J., May 24, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions by utilizing a natural transport system in the blood-brain barrier ("BBB") as a novel delivery ...
2022-05-24 20:00
2149
Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
SHANGHAI, May 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) presented at Digestive Disease Week (DDW) 2022 detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluatin...
2022-05-24 19:00
1466
Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
SHANGHAI, May 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) presented at Digestive Disease Week (DDW) 2022 detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluatin...
2022-05-24 19:00
2118
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO
SYDNEY, May 23, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be presenting at two upcoming investor conferences. Dr Garner will present on behalf of Kazia at the HC ...
2022-05-23 20:30
2821
Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand
The latest geographic growth increases Medison's global footprint across 25
countries in four continents, further strengthening its commercial offering
PETACH TIKVAH, Israel, May 23, 2022 /PRNewswire/ -- Medison Pharma
2022-05-23 20:28
3114
Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas
SHANGHAI and HONG KONG, May 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer...
2022-05-23 10:10
2660
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy, May 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini")...
2022-05-21 01:19
9520
Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited
STOCKHOLM, May 20, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment inJune 2022. T...
2022-05-20 14:56
2331
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, May 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of can...
2022-05-19 22:39
2354
CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays
This acquisition solidifies CellCarta's leadership position in proteomics serviceswith a unique combination of validated set of reagents and multiplex assays, including pathway specific off-the-shelf panels, allowing for clinical protein quantification covering a comprehensive range of immuno-onc...
2022-05-19 20:30
1526
4C Medical Technologies Presents Data from the Global Clinical Experience for the AltaValve Early Feasibility Study at AATS 2022
MINNEAPOLIS, May 19, 2022 /PRNewswire/ -- 4C Medical Technologies, Inc. ("4C Medical" or the "Company"), a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease, presented its global clinical experience from its initial A...
2022-05-19 20:06
2059
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
SHANGHAI and GAITHERSBURG, MD., May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at 8 a.m. EST on...
2022-05-19 20:00
1624
Berry Oncology Launches an Innovative Self-Iterative "HIFI" System
BEIJING, May 18, 2022 /PRNewswire/ -- Berry Oncology, a leading company in the global industry for genetic testing and early screening of tumors, recently launched a HIFI system. The HIFI system consists of HIFI-det liquid biopsy technology and the corresponding HIFI-cal series of algorithms. W...
2022-05-19 09:00
2315
PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding
BOSTON, May 19, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The cente...
2022-05-19 04:56
2525
OriCiro Genomics expand into Boston, Open new office in North America
TOKYO, May 18, 2022 /PRNewswire/ -- OriCiro Genomics K.K. a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapeutics and synthetic biology, today announced the open US office in North America. In the midst of the genomic revolution, OriCiro is on a mi...
2022-05-18 22:00
1867
Laekna Therapeutics Raises $61 Million in Series D financing
SHANGHAI and WARREN, N.J., May 18, 2022 /PRNewswire/ -- Laekna Therapeutics (" Laekna"), a clinical-stage global biotechnology company dedicated to developing next generation medicines to treat cancer and liver diseases, announced that it has raised$61 million in Series D financing led by CS Capit...
2022-05-18 20:00
1796
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 289 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 288 media titles]
2024-04-22 06:00
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 287 media titles]
2024-04-18 21:26
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 284 media titles]
2024-04-19 13:25
Animated Life in Yunnan
[Picked up by 280 media titles]
2024-04-18 14:00
Most Read
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
7405
Animated Life in Yunnan
2024-04-18 14:00
7169
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
2024-04-18 21:26
6947
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
2024-04-19 13:25
5263
IQAX eBL Wins Prestigious APTFF Trade Facilitation Innovation Award 2024
2024-04-18 10:36
3596